Results 31 to 40 of about 98,172 (269)

Out Foxing Bcr-Abl [PDF]

Cancer Biology & Therapy, 2011
Commentary to:Bortezomib treatment causes remission in a Ph+ ALL patient and reveals FoxO as a theranostic markerRajan Dewar, Sing-Tsung Chen, Heather Yeckes-Rodin, Kenneth Miller and Roya Khosravi ...
openaire   +3 more sources

A novel imatinib-upregulated long noncoding RNA plays a critical role in inhibition of tumor growth induced by Abl oncogenes

Molecular Cancer, 2022
Background Dysregulation of long noncoding RNAs (lncRNAs) has been linked to various human cancers. Bcr-Abl oncogene that results from a reciprocal translocation between human chromosome 9 and 22, is associated with several hematological malignancies ...
Yun Ma, Guijie Guo, Tingting Li, Faxin Wen, Jianling Yang, Biao Chen, Xuefei Wang, Ji-Long Chen   +7 more
doaj   +1 more source

Association of Clinical Features and Hematological Laboratories between Ph (+)/BCR-ABL (+) Chronic Myeloid Leukemia and Other Type of Ph/BCR-ABL Chronic Myeloid Leukemia

Jurnal Penyakit Dalam Indonesia, 2018
Introduction. Patients with chronic phase Chronic Myeloid Leukemia (CML) at Hematology-Medical Oncology Clinic Department of Internal Medicine dr. Cipto Mangunkusumo National Hospital who haveperformed cytogenetic and RTPCR BCR-ABL examination showed: Ph
Wulyo Rajabto, A. Harryanto, Hilman Tadjoedin, Kuntjoro Harimurti   +3 more
doaj   +1 more source

USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia

Cell Discovery, 2019
Constitutive activation of tyrosine kinase Bcr-Abl is the leading cause of the development and progression of chronic myeloid leukemia (CML). Currently, the application of tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl is the primary therapy for
Yuning Liao, Ningning Liu, Xiaohong Xia, Zhiqiang Guo, Yanling Li, Lili Jiang, Ruiqing Zhou, D. Tang, Hongbiao Huang, Jinbao Liu   +9 more
semanticscholar   +1 more source

The Ins and Outs of Bcr-Abl Inhibition [PDF]

Genes & Cancer, 2012
The development of inhibitors against Abl has changed the landscape for the treatment of chronic myelogenous leukemia (CML) and cancer in general. Beginning with the monumental discovery and approval of imatinib for CML, a second generation of inhibitors, nilotinib and dasatinib, has now gained approval for the treatment of CML.
E. Premkumar Reddy, Aneel K. Aggarwal
openaire   +2 more sources

Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients

Scientific Reports, 2019
Mutations in the drug binding region of BCR-ABL lead to imatinib resistance during the management of chronic myeloid leukemia (CML). In our study, 62 Philadelphia positive (Ph+) CML patients showing conspicuous expression of BCR-ABL gene were treated ...
C. Chandrasekhar, Pasupuleti Santhosh Kumar, P. Sarma   +2 more
semanticscholar   +1 more source

Development of protein degradation inducers of oncogenic BCR‐ABL protein by conjugation of ABL kinase inhibitors and IAP ligands

Cancer Science, 2017
Chromosomal translocation occurs in some cancer cells, which results in the expression of aberrant oncogenic fusion proteins that include BCR‐ABL in chronic myelogenous leukemia (CML).
N. Shibata, Naoki Miyamoto, Katsunori Nagai, K. Shimokawa, Tomoya Sameshima, Nobumichi Ohoka, T. Hattori, Y. Imaeda, H. Nara, N. Cho, M. Naito   +10 more
semanticscholar   +1 more source

Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias

Advances in Hematology, 2015
BCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia (ALL), are the paradigm of targeted molecular therapy of cancer due to the impressive clinical responses obtained with BCR-ABL ...
Alessandro Morotti, Giovanna Carrà, Cristina Panuzzo, Sabrina Crivellaro, Riccardo Taulli, Angelo Guerrasio, Giuseppe Saglio   +6 more
doaj   +1 more source

circCRKL, a circRNA derived from CRKL, regulates BCR-ABL via sponging miR-877-5p to promote chronic myeloid leukemia cell proliferation

Journal of Translational Medicine, 2022
Background The BCR-ABL fusion protein is the key factor that results in the occurrence of chronic myeloid leukemia (CML). Imatinib (IM) is a targeted inhibitor of BCR-ABL to achieve complete remission.
Jianming Wang, Yang Liang, Yuefeng Qin, Guoyun Jiang, Yuhang Peng, Wenli Feng   +5 more
doaj   +1 more source

Targeting the Allosteric Site of Oncoprotein BCR-ABL as an Alternative Strategy for Effective Target Protein Degradation.

ACS Medicinal Chemistry Letters, 2017
Protein degradation technology based on hybrid small molecules is an emerging drug modality that has significant potential in drug discovery and as a unique method of post-translational protein knockdown in the field of chemical biology.
K. Shimokawa, N. Shibata, Tomoya Sameshima, Naoki Miyamoto, O. Ujikawa, H. Nara, Nobumichi Ohoka, T. Hattori, N. Cho, M. Naito   +9 more
semanticscholar   +1 more source